{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.4","upperLimit":"14.4","value":"11.4"},{"groupId":"OG001","lowerLimit":"15.7","upperLimit":"24.7","value":"20.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"One year overall survival of concurrent cetuximab and nivolumab in patients with recurrent and/or metastatic HNSCC. OS: The length of time from the start of treatment until death by any cause.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients who had progressed on at least one prior line of treatment for their recurrent and/or metastatic HNSCC\n\nParticipants were treated with Nivolumab and Cetuximab at recommended Phase II dose (RP2D). Nivolumab: Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms. Cetuximab: Cetuximab intravenously (IV) at 500 mg/m\\^2 or 250 mg/m\\^2 as outlined in the treatment arms.","id":"OG000","title":"Phase I Lead in + Phase II: Cohort A"},{"description":"Patients who have not had any prior treatment for their recurrent and/or metastatic HNSCC\n\nParticipants were treated with Nivolumab and Cetuximab at recommended Phase II dose (RP2D). Nivolumab: Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms. Cetuximab: Cetuximab intravenously (IV) at 500 mg/m\\^2 or 250 mg/m\\^2 as outlined in the treatment arms.","id":"OG001","title":"Phase II - Cohort B"}],"paramType":"MEDIAN","populationDescription":"Evaluable participants","reportingStatus":"POSTED","timeFrame":"Up to 24 months","title":"Phase II: Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}